Literature DB >> 9595389

Endothelin peptide and converting enzymes in human endothelium.

F D Russell1, J N Skepper, A P Davenport.   

Abstract

Sites linked to the storage and transportation of endothelin (ET) were investigated in human coronary artery. ET-like immunoreactivity was detected in secretory vesicles and storage granules, indicating that the peptide may be transported via both constitutive and regulated secretory pathways. The distribution of ECE-like immunoreactivity was also investigated to determine possible sites involved in the cleavage of big ET-1 to ET-1. Sections of coronary artery labeled with antisera raised against the endothelin-converting enzymes (ECE-1 alpha, ECE-1 beta, and ECE-2) showed immunoreactive staining over luminal endothelial cells. An en face coronary artery preparation labeled with antisera raised against ECE-1 alpha and ECE-1 beta revealed only a low level of plasma membrane staining by scanning electron microscopy. The findings indicate cell surface and intracellular expression of ECE in human endothelium.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9595389     DOI: 10.1097/00005344-199800001-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Secretory pathways in endothelin synthesis.

Authors:  F D Russell; A P Davenport
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors.

Authors:  Parviz Afiatpour; Jamshid Latifpour; Wataru Takahashi; Makoto Yono; Harris E Foster; Kazuyoshi Ikeda; Mehdi Pouresmail; Robert M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-17       Impact factor: 3.000

Review 3.  Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease.

Authors:  D Lominadze; W L Dean; S C Tyagi; A M Roberts
Journal:  Acta Physiol (Oxf)       Date:  2009-09-01       Impact factor: 6.311

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.